Better Mental Health
for More People
We are at a crisis point
in mental health provision.
Mental health and addiction (including alcohol), is the 5th leading cause of illness globally, affecting 20% of the world’s population.
Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.
The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change mental health services and deliver significantly better patient outcomes.
Awakn Life Sciences is a clinical-biotech company researching, developing, and delivering evidenced-based psychedelic medicine to treat Addiction and other mental health conditions.
We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Clinics, and Ecosystems.
We have a dual strategic focus to develop and commercialise proprietary psychedelic therapies and New Molecular Entity drugs to treat Addiction and other mental health conditions in a chain of medical psychedelic clinics across the UK and EU.
Our goals are to be a global leader in the research of psychedelic therapies and New Molecular Entity drugs to treat Addiction, build the UK and EU’s leading chain of medical psychedelic clinics, and scale our reach through our Partnerships Ecosystem.
Clear IP development pathway
• New Molecular Entity drugs
• Clinical trials
Global research leaders in psychedelic treatments
Dr. Ben Sessa led the world’s only MDMA and AUD study (BIMA) and Prof. Celia Morgan led the world’s leading Ketamine AUD study (KARE)
The leading scientific and medical team in the industry
Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Prof. Matt Johnson, Dr. Michael Mithoefer, and Ann Mithoefer
Strategic partnerships with two leading UK universities for exclusive access to data and findings from recent clinical trials
Scalable Revenue Streams
• Clinic revenue starting in Q1 2021
• Licensed Methods of Treatment 2022 onwards
Significant first mover advantage in UK and EU
400m people and US$19trn GDP
Our business consists of three related and complementary divisions: Research, Digital, Clinics, and Ecosystems.
Our team has led the research that has defined the psychedelic medicine industry, including: the Bristol Imperial MDMA for Alcoholism (BIMA) study and the Ketamine for Reduction of Alcoholic Relapse (KARE).
We have a portfolio of drug development and clinical trials planned and initiated focused on treating addiction.
We provide hope for those whom the status quo is not working by combining the proven therapeutic potential of ketamine with psychotherapy to treat Addiction, Anxiety, Depression, and PTSD.
• Bristol Q1 2021
• London 1 & Manchester 2021
• London 2, Birmingham, Dublin (Ireland) 2022
• Continental Europe 2023+
Awakn Partnerships Ecosystems
Scale our reach beyond our core territories through licencing to enable addiction treatment practitioners deliver the Awakn methodology:
• Protocols & Therapy
• Clinic Design Best Practice
• Data, Analytics, Insights
Scientific Advisory Team
Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry
Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt
Awakn announces intent to pursue qualifying transaction in preparation for listing on the NEO exchange in Canada
Awakn acquires IP from a Phase II KAP Trial for AUD from the University of Exeter
Dr. Ben Sessa about the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial
Awakn Appoints James Collins as Chief Operating Officer